FMC enters its Q2 print on July 30 having shed 8.5% on Tuesday alone — the stock now trades at $10.01, down 15% on the week and down roughly 15% over the past month, making today's release a genuine test of whether the bear thesis has run ahead of reality.
The short position remains the defining feature of the setup, and yesterday's selloff hasn't changed the structure. Short interest held at 21.9% of the free float as of July 28 — a level that has risen 55% over the past 30 days, from roughly 14% of float at end-June. That build has been deliberate: the lending market stays wide open, with availability running at 407%, meaning four shares remain available to borrow for every one already on loan, and the cost to borrow is just 0.50%. Shorts haven't been squeezed out; they've added into easy borrow conditions, and the six-day cover ratio means unwinding the position is no quick exercise. One notable development: yesterday's price drop didn't appear to trigger fresh short covering, suggesting bears see the selloff as confirmation rather than capitulation. Options positioning has sharpened since the prior article — the put/call ratio climbed to 0.35 on Tuesday, nearly four standard deviations above its 20-day average of 0.31, its highest reading in almost a year. That's a sharp defensive move for a stock where options traders have largely stayed calm through the buildup.
The analyst community has been consistent in one direction: lower. Barclays cut its target to $11 from $13 on July 27, maintaining Underweight. RBC trimmed to $12 from $14 on July 21. Both moves came after Citigroup shaved its target to $14 in late June. The consensus mean sits at $15.35 — still above the current price, implying theoretical upside — but the trajectory is clearly downward, and no firm has upgraded or raised a target since May. The bull case rests on management's stated confidence in $600 million implied EBITDA in H2 2026, driven by Latin American seasonal volumes and U.S. momentum in Q2. Bears point to a 9% price decline in Q1, volume weakness, and below-consensus Q2 guidance that has already disappointed once. Valuation offers little comfort to either side: the stock trades at 5.9x trailing earnings and 6.9x EV/EBITDA — cheap in isolation, but the EPS momentum score ranks in the 17th percentile on a 30-day basis, and the short score of 65.5 has been drifting higher through July, placing FMC in the 3rd percentile of short-score rankings universe-wide. Peers have diverged sharply on the week: CTVA gained 2.3%, MOS added 5%, while FMC fell 15% — a gap that underscores the company-specific nature of the pressure rather than broad sector weakness.
The earnings report will test a narrow but consequential question: whether H2 volume recovery is real enough to justify holding the stock at $10, or whether the bears who built aggressively through July have correctly anticipated another guidance cut.
See the live data behind this article on ORTEX.
Open FMC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
